Background. Outpatient parenteral antimicrobial therapy (OPAT) can be managed by specialists in infectious diseases (ID) or by other physicians. Better management of OPAT can reduce the likelihood of readmission or emergency department (ED) use. The relative success of ID specialists and other physicians in managing OPAT has received little study.
Outpatient parenteral antimicrobial therapy (OPAT) can reduce the length of hospital stays and save money when delivered appropriately to reliable, medically stable patients [1] . Clinical guidelines published by the Infectious Diseases Society of America [2] offer detailed guidance on the selection of patients, medication regimens, and related issues. OPAT is often planned or monitored by an infectious disease (ID) specialist, but physicians in several other specialties also prescribe OPAT.
ID physicians are not always consulted during the initial hospitalization or emergency department (ED) visit in which an infection is diagnosed, nor during the planning or monitoring of OPAT. Studies consistently find that when ID specialists are consulted after OPAT has been prescribed, for a majority of patients they recommend changes in an antimicrobial agent, format, dosage, or duration, or note that OPAT is unnecessary [3] [4] [5] [6] .
Differences in prescribing should lead to observable differences in patient outcomes. To date, though, only a single study has compared outcomes between OPAT cases directed by an ID specialist (ID-led) and OPAT cases without ID-specialist direction (Other OPAT). Keller et al. [7] analyzed data on 488 patients in a single academic medical center. While those with ID-led OPAT had fewer errors in prescribing, were more likely to obtain laboratory testing, and had better follow-up, there were not significant differences in 60-day hospital or ED admission rates between ID-led and Other OPAT cases.
It is difficult to ascertain the external validity of studies from a single center. We therefore analyzed OPAT using a broad-based national database of insurance claims. We chose 3 outcomes based on their importance to providers, insurers, and patients: hospital admission, ED admission, and total payments for healthcare. Our goal was to determine the impact of ID guidance on OPAT outcomes, controlling for patient and provider factors as much as claims data would allow. Although the data represent a convenience sample, their national scope should lead to reliable conclusions about the impact of ID physician guidance.
METHODS

Data
We performed a retrospective analysis of administrative claims from the IBM® MarketScan® Research Databases. The MarketScan Commercial Database contains the eligibility, inpatient, outpatient, and outpatient prescription-drug experience of several million employees and their dependents annually, covered under a variety of fee-for-service and capitated health plans. The MarketScan Medicare Supplemental Database contains the healthcare experience of individuals with Medicare supplemental insurance paid for by employers. We extracted claims from each database for events occurring between January 2012 and December 2014. All index events (described below) occurred between January 2013 and November 2014.
Inclusion and Exclusion Criteria
Index events consisted of ED visits or inpatient stays in acutecare hospitals with a primary or secondary diagnosis of any of these infections: soft-tissue infection, prosthetic joint infection, other septic arthritis, meningitis, osteomyelitis, bacteremia, bacterial endocarditis, or vascular device infection, which included any central-line-associated bloodstream infection. Associated diagnosis codes appear in the online appendix (Supplementary Data). Primary and secondary diagnosis codes and procedures were used to locate each condition or transplant procedure. Other inclusion criteria included continuous enrollment in the same health insurance plan for the 6 months prior to admission and for 30 days beyond discharge, an admission type of medical or surgical, and age under 65 at time of admission.
We dropped claims if any of these exclusion criterion applied: an acute-care hospitalization for any cause in the 30 days prior to the index event; an acute-care hospitalization for the same cause as the index event in the 6 months prior to the index stay, based on primary or secondary diagnoses; discharge to an acutecare hospital from the index event; an index event that ended in death; or an acute-care hospitalization in the first 7 days after discharge, unless OPAT began prior to the readmission.
Finally, we excluded individuals who did not have evidence of OPAT in the 14 days after discharge from the index event.
OPAT was identified by procedure codes (see online appendix in the Supplementary Data).
Variables
The initial analytic file included patient indicators for gender and 5 age groups, a census division of the hospital or ED, and the index stay type (ED or, for hospitalizations, either medical or surgical). Several variables captured the clinical characteristics of the index stay: initial infection; Major Diagnostic Category; Agency for Healthcare Research and Quality comorbidity indicators; modified Elixhauser Comorbidity Index [8] ; count of Charlson comorbidity categories based on the index event (0, 1, 2 or more); number of 3-digit International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) discharge diagnoses assigned in the index event; average number of non-hospitalist consults per day (expressed as deciles of that distribution); whether the stay included time in an intensive care unit (ICU); and whether the patient received OPAT at home. A hospital was indicated as rural if it was located outside a Metropolitan Statistical Area. Payment models also featured an indicator of enrollment in a capitated health plan.
The key variable is an indicator for ID-led OPAT. We considered the entire course of OPAT to be ID-led if the patient had an outpatient consultation with an ID specialist after the index hospitalization and within 14 days before or after the first claim for OPAT, as indicated by the provider type on the claim. Any OPAT episode without evidence of ID specialist involvement was labeled as "Other OPAT. "
Outcome variables pertained to the first 30 days after discharge from the index ED visit or hospital stay. They included the probability of ED admission, probability of hospital admission, and total spending. Total spending equaled the sum of payments by all payers, including any coordination-of-benefit payments and payments by the patient. Payments covered all settings of care.
Statistical Analyses
Through propensity-score matching, we created 2 cohorts with similar likelihoods of having ID-led OPAT. Cases with ID-led OPAT were matched 1-to-1 with Other OPAT cases through nearest-neighbor matching without replacement, with a caliper of 0.03. The balance across matched cohorts was assessed by paired t-tests, standardized mean difference, and common support. Table 1 lists regressors in the matching model: patient age-category and gender; the initial infection; Agency for Healthcare Research and Quality comorbidity indicators; indicators for infection with methicillin-resistant Staphylococcus aureus and Pseudomonas; the count of major diagnosis categories; the count of specialists consulted; the type of index stay (ED or, for hospitalizations, either medical or surgical); and the rural status and geographic region of the hospital.
We developed descriptive statistics (mean, standard deviation) for person-and hospital-level variables. Separate regression models were run for each outcome variable, with logistic models for ED and hospital admissions and generalized linear models with log link and gamma distribution for spending. Through bootstrapping, we developed 95% confidence intervals for each coefficient. Table 1 lists the independent variables in the models.
In some cases, low-frequency categories were lumped into a single, omitted category (such as all transplants other than lung or kidney). Analyses were performed using SAS statistical software.
RESULTS
We identified 10 818 index events followed by OPAT, of which 4317 (39.9%) were ID-led. Inpatient admissions accounted for over 92% of index events.
Most variables were statistically significant in the propensity scoring model (see online appendix in Supplementary Data). Nearly 95% of individuals with ID-led OPAT (n = 4100) could be matched to someone with Other OPAT. The matched cohorts were well balanced. The absolute value of standardized differences was less than 0.02 for all independent variables. Table 2 presents the frequencies of the baseline variables, including initial infections and selected other characteristics. Soft-tissue infection and osteomyelitis were the most common infections in the index event, with each affecting more than 40% of individuals. Other septic arthritis, bacterial endocarditis, and bacteremia were each diagnosed in 20-26% of the study cohorts, while all other conditions represented less than 3-11% each. More than half of hospital stays were surgical (58%) rather than medical. Nearly 1 in 5 stays (19.3%) included an ICU segment.
Nearly half of patients were aged 55-64, and 38% were female. About 65% of cases in both groups were in the South and North Central regions, reflecting the distribution of MarketScan data during the study years. Rural locations accounted for 11.1% of cases. Capitated health plans, which tend to report slightly lower total spending than other plans, were slightly more common in the Other OPAT cohort (10.7%) than in the ID-led OPAT cohort (9.1%). Table 3 presents the mean values of the outcome variables. Patients in the ID-led OPAT group had lower rates of 30-day admissions to the hospital (6.2% vs 9.4% for Other OPAT; P < .001). The ID-led OPAT group had higher rates of allcause 30-day admissions to the ED when all ED visits were considered (4.2% vs 2.9% for Other OPAT; P < .001). Once we excluded weekend ED admissions to obtain OPAT services and ED admissions which (for those in the ID-led OPAT group) occurred prior to the first outpatient ID consultation, then the ID-led OPAT group had lower rates of 30-day ED admissions (1.3% vs. 2.6% for Other OPAT; P < .001). Average spending over the 30 days totaled about $34 000, which represents not only ED and inpatient acute-care stays, but also any other health care services that were submitted to an insurance carrier for payment. The cost did not differ significantly across groups. Table 4 shows selected results of 3 regression models of the post-discharge period. Regression coefficients are represented by odds ratios (ORs) for logistic models and marginal effects in dollars for total payments. Full results for all variables appear in the online appendix.
ID-led OPAT was associated with substantially lower odds of ED admissions (OR 0.449, 95% confidence interval [CI] 0.311-0.645). Lower odds of ED admission were associated with a c We counted up to 27 physician specialties. Excluded were supportive specialties, such as pathology and radiology; specialties unrelated to this study, such as optometry, neonatology, and sports medicine; and certain others that are not filled by physicians or do not make bedside consultations. d Payment models only.
e Emergency department readmission model only.
diagnosis of bacteremia, location in the North Central or South regions (relative to the Northeast, the omitted category), and a surgical stay rather than a medical stay. Diagnoses of osteomyelitis and other septic arthritis were associated with greater odds of an ED admission. ID-led OPAT was associated with a large and statistically significant reduction in the odds of hospitalization (OR 0.661, 95% CI 0.557-0.791). Lower odds of hospitalization were also significantly associated with soft-tissue infections, prosthetic joint infections, osteomyelitis, other septic arthritis, vascular device infections, and locations outside of the Northeast. Having an ICU segment in the index stay was significantly associated with a higher chance of an inpatient admission.
Patients with ID-led OPAT accumulated $1487.56 less in total healthcare payments (95% CI -$2688.56--$266.58) during the first 30 days after an index event. This reflects the lower rates of hospital admissions and ED admissions, as well as any differences, positive or negative, in the costs of outpatient care and other forms of inpatient care. Higher 30-day spending was associated with prosthetic joint infections, meningitis, vascular device infections, bacterial endocarditis, bacteremia, an ICU segment during the initial stay, being in the West region (relative to the Northeast), and a surgical index stay.
DISCUSSION
In an analysis of patients on Medicare, Schmitt and others [9] found that ID consultation in the hospital was linked to lower mortality, shorter lengths of stays, and lower costs. Here, we provide the first evidence of similar benefits from ID consultations during OPAT in a broad-based sample of patients treated by a large number of providers from across the United States.
We found that ID consultations during OPAT were associated with much lower rates of hospital and ED admissions during the first 30 days after index events. These results differ sharply from those of Keller and colleagues [7] , who studied 488 patients that were treated at 1 academic medical center. They found no difference in 60-day hospitalizations or ED visits between people with and without ID consultations during OPAT, although people with ID consultations were more likely to have appropriate antimicrobial therapy and had more laboratory tests and follow-up visits. A potential explanation is that the medical center they studied had unusually guideline-concordant care by non-ID physicians. In a study of other hospitals, Shah and others [6] found that ID consultations during OPAT are associated with more monitoring, but not with serum levels of vancomycin or aminoglycosides. If similar care is provided at the medical center studied by Keller and colleagues, it might explain a lack of differences in the clinical outcomes.
The time period may be important, as well. Relative to our 30-day period, the 60-day period used by Keller et al. [7] captured more OPAT-related admissions, but also more unrelated admissions. The greater the proportion of unrelated admissions, the lesser the measured impact of ID consultations.
Our definition of ID involvement relied on the standardized provider-type field found on outpatient insurance claims. Some values of the field refer not to the physician's specialty, however, but to the organization, such as with clinics. In addition, ID specialists with a board certification in internal medicine could also appear in claims data as internal medicine specialists. For these reasons, the Other OPAT group may include some individuals whose treatment was guided by an ID specialist. Potential contamination of this kind is undesirable, because it could dilute the estimated coefficients on ID specalists' involvement. As a result, the difference between ID-led and Other OPAT could be even greater than we observed. Hospital admission rates over 30 days or more have varied widely across studies of OPAT, from 1-3% [10, 11] to 14% [12] , to 20% or more [13] [14] [15] . The 8% rate in our data-which excluded people with any hospitalization in the 30 days prior to the index event-falls in the lower middle of this range. The considerable variation in rates across studies could reflect differences in guideline adherence in monitoring and medication. Medical centers and individual physicians will also vary in their propensity to prescribe OPAT, based on local customs, patients' clinical characteristics, and environmental factors that could affect the feasibility of OPAT. An important area for future research is to better understand the relationship between guideline-concordant care and admission to a hospital or ED.
Only a few studies have analyzed ED admission during or after OPAT. The most similar to ours was a case series of 8263 patients from the Cleveland Clinic [12] . It yielded a rate of 4.6% over 30 days, a little higher than the 3.6% rate in our sample from across the United States. The higher rate could reflect the unusual case mix of a major tertiary-care center.
The continuity of care provided by ID involvement may contribute to the better outcomes seen with ID-led OPAT. If patients move between settings of care, each handoff will require a new practitioner to become familiar with the patient. If the treating ID physician remains the same across settings, however, it may lead to better and more efficient care.
A few studies have considered long-term outcomes after ID consultation for conditions beyond those studied here. In 1 study, ID consultation reduced 30-day and 1-year mortality rates following multidrug-resistant organism infections [16] . Another saw reduced 90-day mortality rates from Candida glabrate fungaemia among persons with cancer [17] . In both cases, patients with ID consultations were more likely to receive guideline-adherent medications and procedures.
We acknowledge several limitations of our analysis. Patients were not randomized, and even after propensity scoring the 2 cohorts could differ by unobserved factors that relate to spending and to hospital and ED admissions. Administrative claims data do not contain laboratory results that would enable us to control closely for patient-level health differences. The generalizability of these results may be limited, due to the inability of the data to answer key questions about prognoses and specific patient comorbidities or characteristics. Finally, as noted earlier, it is possible that some patients in the Other OPAT cohort actually received ID consultations. This could arise, for example, if the OPAT formed part of a bundle of services in a bundled-payment or episode-of-care model. Regressions also included an intercept term and indicators for Major Diagnostic Category, Charlson Comorbidity Index, gender, and age group. The ED readmission model had an indicator for home-based OPAT. The payment model had an indicator for capitated payment plans.
Abbreviations: CI, confidence interval; ED, emergency department; ICU, intensive care unit; ID, infectious disease; OPAT, outpatient parenteral antimicrobial therapy. a P < .05.
